IO-202

N/A

Report date: 2025/06/18 14:58:44
First In Class

Base Information

Drug NameIO-202
Drug Alias NameIO-202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsSolid tumoursLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesYiming Biomedical Technology (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesYiming Biomedical Technology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A